Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
|Videos|June 9, 2017
Ilana Cass on Potential Consequences of Preventive Surgery
Author(s)Ilana Cass, M.D.
Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.
Advertisement
Ilana Cass, M.D. of Cedars-Sinai Medical Center, discusses the potential side effects that may occur after a preventive surgery for ovarian cancer. Some of the effects are yet unknown and standards for screening need to be developed.
Advertisement
Related to this article
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
Advertisement
Advertisement
Trending on CURE
1
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
2
Keytruda After Kidney Cancer Surgery Lowers Risk of Death by 30%
3
ACA Open Enrollment 2027: What Patients With Cancer Should Check
4
Sac-TMT Plus Keytruda Improves Outcomes in PD-L1-Negative Lung Cancer
5